(19)
(11) EP 4 739 314 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24739547.8

(22) Date of filing: 04.07.2024
(51) International Patent Classification (IPC): 
A61K 31/496(2006.01)
A61K 31/506(2006.01)
 A61P 9/10(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/496; A61P 9/10; A61K 31/506
(86) International application number:
PCT/EP2024/068835
(87) International publication number:
WO 2025/008449 (09.01.2025 Gazette 2025/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 05.07.2023 EP 23306131

(71) Applicants:
  • Institut National de la Santé et de la Recherche Médicale
    75013 Paris (FR)
  • Université Paris Cité
    75006 Paris (FR)

(72) Inventors:
  • TALEB, Soraya
    75015 Paris (FR)
  • CHAJADINE, Mouna
    75015 Paris (FR)

(74) Representative: Inserm Transfert 
PariSanté Campus 10 rue d'Oradour-sur-Glane
75015 Paris
75015 Paris (FR)

   


(54) USE OF TRYPTOPHAN HYDROXYLASE 1 (TPH1) INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS